查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1708012

全球液態切片市場：行業分析、規模、佔有率、成長、趨勢和預測（2025-2032）

Lung Cancer Liquid Biopsy Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 180 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

主要發現

  • 肺癌液態切片市場規模：8.247億美元（2025年）
  • 預計市場價值：19.5億美元（2032年）
  • 全球市場成長率：12.7%（2025年至2032年的複合年成長率）

肺癌液態切片市場 - 報告範圍

肺癌液態切片市場專注於利用血液和其他體液檢測肺癌患者的腫瘤生物標記的非侵入性診斷方法。這些切片檢查正在徹底改變癌症的診斷和管理，具有快速的周轉時間、減少患者的不適以及即時監測腫瘤進展和治療反應等特徵。隨著全球肺癌發生率的上升和精準醫療的普及，液態切片正成為腫瘤診斷的強大工具。該市場涵蓋廣泛的產品和服務，包括專為小細胞肺癌（SCLC）和非小細胞肺癌（NSCLC）的早期檢測、基因分析和治療指導而設計的儀器、試劑和生物資訊解決方案。

市場成長動力

全球肺癌液態切片市場的成長主要受到全球肺癌盛行率上升和微創診斷方法需求增加的推動。分子診斷技術的進步，特別是次世代定序（NGS）和基於PCR的技術，使得液態切片測試更加準確和容易獲得。此外，對個人化醫療的日益關注鼓勵醫療保健提供者和腫瘤學家採用液態切片進行即時腫瘤分析和監測。支持性監管核准和不斷增加的醫療保健支出（尤其是在已開發國家）進一步促進了市場的擴張。人們對早期和準確的癌症檢測方法的日益成長的偏好以及液態切片在克服傳統組織切片檢查局限性方面的潛力也在推動市場需求。

市場限制

儘管成長軌跡看好，液態切片市場仍面臨幾個挑戰。先進液態切片技術的高成本可能會限制其應用，尤其是在中低收入國家。一些檢測的敏感性和特異性仍然令人擔憂，特別是在早期癌症檢測中，因為它們可能會產生假陽性或假陰性。一些地區患者和醫療保健提供者的認知度較低也阻礙了市場滲透。此外，嚴格的法規結構和報銷障礙可能會延遲產品發布或限制獲取，從而影響整體市場的成長。

市場機會

由於對細胞外囊泡和循環性腫瘤細胞等新型生物標記的研究不斷擴大，可以提高診斷的準確性，因此液態切片市場提供了重大機會。多分析液態切片面板的持續發展以及人工智慧和機器學習在生物資訊學中的整合為提高診斷準確性和效率提供了途徑。新興經濟體，尤其是亞太和拉丁美洲的新興經濟體，由於癌症發病率的上升和醫療保健基礎設施的擴大，擁有尚未開發的潛力。此外，診斷公司和製藥公司在標靶治療的伴同性診斷方面的合作正在開闢新的成長途徑。持續投資於旨在檢驗新的生物標記組合的研發和臨床試驗將推動創新和市場競爭力。

本報告研究了全球液態切片市場，並對市場動態進行了詳細分析，包括成長動力、趨勢、機會和挑戰。

目錄

第1章執行摘要

第2章 市場概述

  • 市場範圍和定義
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
    • 主要趨勢
  • 宏觀經濟因素
    • 全球產業展望
    • 全球GDP成長前景
  • COVID-19影響分析
  • 預測因子－相關性和影響力

第3章 增值考慮

  • 產品採用分析
  • 疾病流行病學
  • 監管格局
  • 供應商名單
  • 波特五力分析
  • PESTLE分析
  • 主要企業促銷策略

第4章 全球肺癌液態切片展望

  • 主要亮點
    • 市場規模及與前一年同期比較
    • 絕對的商機
  • 市場規模分析與預測
    • 市場規模表現分析（2019-2024）
    • 當前市場規模分析與預測（2025-2032）
  • 全球肺癌液態切片展望：產品
    • 簡介/主要發現
    • 市場規模績效分析：依產品（2019-2024 年）
    • 目前市場規模分析及產品預測（2025-2032）
      • 裝置
      • 套件和試劑
      • 軟體、服務
    • 市場吸引力分析：產品
  • 全球肺癌液態切片展望：技術
    • 簡介/主要發現
    • 依技術分類的市場規模表現（2019-2024 年）
    • 目前市場規模分析及技術預測（2025-2032）
      • 多基因平行分析（NGS）
      • 單基因分析（PCR微陣列）
    • 市場吸引力分析：技術
  • 全球液態切片展望：生物標記
    • 簡介/主要發現
    • 生物標記市場規模表現（2019-2024）
    • 生物標記目前市場規模分析及預測（2025-2032）
      • cfDNA
      • ctDNA
      • 細胞外囊泡（EVs）
      • 循環性腫瘤細胞（CTC）
      • 其他
    • 市場吸引力分析：生物標記
  • 全球肺癌液態切片展望：適應症
    • 簡介/主要發現
    • 市場規模表現（依適應症分類） (2019-2024)
    • 目前市場規模分析及預測（2025-2032）
      • 小細胞肺癌（SCLC）
      • 非小細胞肺癌（NSCLC）
    • 市場吸引力分析：跡象
  • 全球液態切片展望：樣本
    • 簡介/主要發現
    • 市場規模表現（依樣本）（2019-2024 年）
    • 目前市場規模分析及樣本預測（2025-2032）
      • 血
      • 腦脊髓液（CSF）
      • 電漿
      • 血清
      • 其他
    • 市場吸引力分析：範例
  • 全球肺癌液態切片展望：最終用戶
    • 簡介/主要發現
    • 最終用戶的市場規模表現（2019-2024）
    • 目前市場規模分析及最終用戶預測（2025-2032）
      • 醫院
      • 參考實驗室
      • 學術研究所
      • 其他
    • 市場吸引力分析：最終用戶

5. 全球肺癌液態切片地區展望

  • 主要亮點
  • 市場規模績效分析：按地區（2019-2024）
  • 目前市場規模分析及各地區預測（2025-2032）
    • 北美洲
    • 歐洲
    • 東亞
    • 南亞和大洋洲
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力分析：地區

6. 北美肺癌液態切片展望

7. 歐洲肺癌液態切片展望

第8章 東亞肺癌液態切片展望

9. 南亞和大洋洲肺癌液態切片展望

10. 拉丁美洲肺癌液態切片前景

11. 中東和非洲肺癌液態切片展望

第12章競爭格局

  • 市場佔有率分析（2025年）
  • 市場結構
    • 競爭強度圖：按市場
    • 競爭儀錶板
  • 公司簡介（詳情－概述、財務狀況、策略、最新發展）
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Oncocyte Corporation
    • NeoGenomics Laboratories
    • Lepu Medical Technology (Beijing) Co., Ltd
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc.
    • F. Hoffmann-La Roche Ltd
    • Sysmex Corporation
    • BioView
    • Guardant Health, Inc
    • SOPHiA GENETICS
    • BioMark Diagnostics
    • DELFI Diagnostics, Inc.
    • Freenome Holdings, Inc.
    • Foresight Diagnostics, Inc.
    • Foundation Medicine, Inc.
    • Pillar Biosciences, Inc.
    • Caris Life Sciences

第13章 附錄

簡介目錄
Product Code: PMRREP35195

Persistence Market Research has recently released a comprehensive report on the global Lung Cancer Liquid Biopsy Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Lung Cancer Liquid Biopsy Market Size (2025E): US$ 824.7 Mn
  • Projected Market Value (2032F): US$ 1,900.5 Mn
  • Global Market Growth Rate (CAGR 2025 to 2032): 12.7%

Lung Cancer Liquid Biopsy Market - Report Scope:

The lung cancer liquid biopsy market focuses on non-invasive diagnostic methods that utilize blood and other body fluids to detect tumor biomarkers in lung cancer patients. These biopsies are revolutionizing cancer diagnostics and management by offering quicker turnaround times, reduced patient discomfort, and real-time monitoring of tumor progression or therapy response. With rising lung cancer incidence globally and increasing adoption of precision medicine, liquid biopsy is emerging as a powerful tool in oncology diagnostics. This market includes a wide range of products and services, including instruments, reagents, and bioinformatics solutions designed for early detection, genetic profiling, and therapeutic decision-making in both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC).

Market Growth Drivers:

The growth of the global lung cancer liquid biopsy market is being significantly driven by the rising global prevalence of lung cancer, coupled with a growing demand for minimally invasive diagnostic procedures. Technological advancements in molecular diagnostics, particularly in next-generation sequencing (NGS) and PCR-based techniques, are making liquid biopsy tests more accurate and accessible. Additionally, increasing focus on personalized medicine is pushing healthcare providers and oncologists to adopt liquid biopsies for real-time tumor profiling and monitoring. Supportive regulatory approvals and increasing healthcare spending, especially in developed nations, are further contributing to market expansion. The growing preference for early and precise cancer detection methods and the potential of liquid biopsies to overcome limitations of traditional tissue biopsies are also propelling market demand.

Market Restraints:

Despite the promising growth trajectory, the lung cancer liquid biopsy market faces several key challenges. High costs associated with advanced liquid biopsy technologies can restrict adoption, particularly in low- and middle-income countries. The sensitivity and specificity of some assays, especially in early-stage cancer detection, remain areas of concern, potentially leading to false positives or negatives. Limited awareness among patients and healthcare providers in certain regions further impedes market penetration. Additionally, stringent regulatory frameworks and reimbursement hurdles can delay product launches and limit accessibility, affecting overall market growth.

Market Opportunities:

The lung cancer liquid biopsy market presents considerable opportunities fueled by the expansion of research into new biomarkers, including extracellular vesicles and circulating tumor cells, which can enhance diagnostic accuracy. The ongoing development of multi-analyte liquid biopsy panels and integration of AI and machine learning in bioinformatics offer pathways to improved diagnostic precision and efficiency. Emerging economies, especially across Asia-Pacific and Latin America, represent untapped potential with growing cancer burden and expanding healthcare infrastructure. Furthermore, collaborations between diagnostic companies and pharmaceutical firms for companion diagnostics in targeted therapies are opening new growth avenues. Continued investment in R&D and clinical trials aimed at validating new biomarker combinations will likely drive innovation and market competitiveness.

Key Questions Answered in the Report:

  • What are the primary factors driving the global lung cancer liquid biopsy market's growth?
  • Which regions and market segments are experiencing the highest demand for lung cancer liquid biopsy diagnostics?
  • How are advancements in genomics and personalized oncology influencing market dynamics?
  • Who are the key players in the lung cancer liquid biopsy market, and what strategies are they adopting to stay competitive?
  • What are the emerging trends and future projections for the global lung cancer liquid biopsy market?

Competitive Intelligence and Business Strategy:

Leading players in the global lung cancer liquid biopsy market, such as Bio-Rad Laboratories, Agilent Technologies, Thermo Fisher Scientific, Illumina, and F. Hoffmann-La Roche, are focusing on developing high-sensitivity diagnostic platforms and expanding their liquid biopsy portfolios. These companies are increasingly investing in strategic collaborations with research institutions and biotech firms to enhance their R&D capabilities. Mergers, acquisitions, and licensing agreements are common strategies aimed at boosting technological integration and expanding global reach. Key players are also emphasizing regulatory approvals and global certifications to gain market trust and improve reimbursement prospects. Efforts to combine multiple biomarkers into single-panel tests and the integration of cloud-based platforms for data interpretation are setting new standards in the field.

Companies Covered in This Report:

  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Oncocyte Corporation
  • NeoGenomics Laboratories
  • Lepu Medical Technology (Beijing) Co., Ltd
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Sysmex Corporation
  • BioView

Market Segmentation

By Product:

  • Instruments
  • Kits and Reagents
  • Software and Services

By Technology:

  • Multi-gene-parallel Analysis (NGS)
  • Single Gene Analysis (PCR, Microarrays)

By Biomarker:

  • Cell-free DNA (cfDNA)
  • Circulating Tumor DNA (ctDNA)
  • Extracellular Vesicles (EVs)
  • Circulating Tumor Cells (CTC)
  • Others

By Indication:

  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)

By Sample:

  • Blood
  • Cerebrospinal Fluid (CSF)
  • Plasma
  • Serum
  • Others

By End-user:

  • Hospitals
  • Reference Laboratories
  • Academic & Research Centers
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Lung Cancer Liquid Biopsy Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Disease Epidemiology
  • 3.3. Regulatory Landscape
  • 3.4. List of Suppliers
  • 3.5. Porter's Five Forces Analysis
  • 3.6. PESTLE Analysis
  • 3.7. Promotional Strategies, By Key Players

4. Global Lung Cancer Liquid Biopsy Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Mn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
  • 4.3. Global Lung Cancer Liquid Biopsy Outlook: Product
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Mn) Analysis, By Product, 2019-2024
    • 4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
      • 4.3.3.1. Instruments
      • 4.3.3.2. Kits and Reagents
      • 4.3.3.3. Software and Services
    • 4.3.4. Market Attractiveness Analysis: Product
  • 4.4. Global Lung Cancer Liquid Biopsy Outlook: Technology
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Mn), By Technology, 2019-2024
    • 4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
      • 4.4.3.1. Multi-gene-parallel Analysis (NGS)
      • 4.4.3.2. Single Gene Analysis (PCR Microarrays)
    • 4.4.4. Market Attractiveness Analysis: Technology
  • 4.5. Global Lung Cancer Liquid Biopsy Outlook: Biomarker
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Mn), By Biomarker, 2019-2024
    • 4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
      • 4.5.3.1. Cell-free DNA (cfDNA)
      • 4.5.3.2. Circulating tumor DNA (ctDNA)
      • 4.5.3.3. Extracellular Vesicles (EVs)
      • 4.5.3.4. Circulating Tumor Cells (CTC)
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: Biomarker
  • 4.6. Global Lung Cancer Liquid Biopsy Outlook: Indication
    • 4.6.1. Introduction / Key Findings
    • 4.6.2. Historical Market Size (US$ Mn), By Indication, 2019-2024
    • 4.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
      • 4.6.3.1. Small Cell Lung Cancer (SCLC)
      • 4.6.3.2. Non-Small Cell Lung Cancer (NSCLC)
    • 4.6.4. Market Attractiveness Analysis: Indication
  • 4.7. Global Lung Cancer Liquid Biopsy Outlook: Sample
    • 4.7.1. Introduction / Key Findings
    • 4.7.2. Historical Market Size (US$ Mn), By Sample, 2019-2024
    • 4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
      • 4.7.3.1. Blood
      • 4.7.3.2. Cerebrospinal Fluid (CSF)
      • 4.7.3.3. Plasma
      • 4.7.3.4. Serum
      • 4.7.3.5. Others
    • 4.7.4. Market Attractiveness Analysis: Sample
  • 4.8. Global Lung Cancer Liquid Biopsy Outlook: End User
    • 4.8.1. Introduction / Key Findings
    • 4.8.2. Historical Market Size (US$ Mn), By End User, 2019-2024
    • 4.8.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
      • 4.8.3.1. Hospitals
      • 4.8.3.2. Reference Laboratories
      • 4.8.3.3. Academic & Research Institutes
      • 4.8.3.4. Others
    • 4.8.4. Market Attractiveness Analysis: End User

5. Global Lung Cancer Liquid Biopsy Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Lung Cancer Liquid Biopsy Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Product
    • 6.2.3. By Technology
    • 6.2.4. By Biomarker
    • 6.2.5. By Indication
    • 6.2.6. By Sample
    • 6.2.7. By End User
  • 6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 6.4.1. Instruments
    • 6.4.2. Kits and Reagents
    • 6.4.3. Software and Services
  • 6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 6.5.1. Multi-gene-parallel Analysis (NGS)
    • 6.5.2. Single Gene Analysis (PCR Microarrays)
  • 6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 6.6.1. Cell-free DNA (cfDNA)
    • 6.6.2. Circulating tumor DNA (ctDNA)
    • 6.6.3. Extracellular Vesicles (EVs)
    • 6.6.4. Circulating Tumor Cells (CTC)
    • 6.6.5. Others
  • 6.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 6.7.1. Small Cell Lung Cancer (SCLC)
    • 6.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 6.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 6.8.1. Blood
    • 6.8.2. Cerebrospinal Fluid (CSF)
    • 6.8.3. Plasma
    • 6.8.4. Serum
    • 6.8.5. Others
  • 6.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 6.9.1. Hospitals
    • 6.9.2. Reference Laboratories
    • 6.9.3. Academic & Research Institutes
    • 6.9.4. Others
  • 6.10. Market Attractiveness Analysis

7. Europe Lung Cancer Liquid Biopsy Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Product
    • 7.2.3. By Technology
    • 7.2.4. By Biomarker
    • 7.2.5. By Indication
    • 7.2.6. By Sample
    • 7.2.7. By End User
  • 7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 7.4.1. Instruments
    • 7.4.2. Kits and Reagents
    • 7.4.3. Software and Services
  • 7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 7.5.1. Multi-gene-parallel Analysis (NGS)
    • 7.5.2. Single Gene Analysis (PCR Microarrays)
  • 7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 7.6.1. Cell-free DNA (cfDNA)
    • 7.6.2. Circulating tumor DNA (ctDNA)
    • 7.6.3. Extracellular Vesicles (EVs)
    • 7.6.4. Circulating Tumor Cells (CTC)
    • 7.6.5. Others
  • 7.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 7.7.1. Small Cell Lung Cancer (SCLC)
    • 7.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 7.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 7.8.1. Blood
    • 7.8.2. Cerebrospinal Fluid (CSF)
    • 7.8.3. Plasma
    • 7.8.4. Serum
    • 7.8.5. Others
  • 7.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 7.9.1. Hospitals
    • 7.9.2. Reference Laboratories
    • 7.9.3. Academic & Research Institutes
    • 7.9.4. Others
  • 7.10. Market Attractiveness Analysis

8. East Asia Lung Cancer Liquid Biopsy Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Product
    • 8.2.3. By Technology
    • 8.2.4. By Biomarker
    • 8.2.5. By Indication
    • 8.2.6. By Sample
    • 8.2.7. By End User
  • 8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 8.4.1. Instruments
    • 8.4.2. Kits and Reagents
    • 8.4.3. Software and Services
  • 8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 8.5.1. Multi-gene-parallel Analysis (NGS)
    • 8.5.2. Single Gene Analysis (PCR Microarrays)
  • 8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 8.6.1. Cell-free DNA (cfDNA)
    • 8.6.2. Circulating tumor DNA (ctDNA)
    • 8.6.3. Extracellular Vesicles (EVs)
    • 8.6.4. Circulating Tumor Cells (CTC)
    • 8.6.5. Others
  • 8.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 8.7.1. Small Cell Lung Cancer (SCLC)
    • 8.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 8.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 8.8.1. Blood
    • 8.8.2. Cerebrospinal Fluid (CSF)
    • 8.8.3. Plasma
    • 8.8.4. Serum
    • 8.8.5. Others
  • 8.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 8.9.1. Hospitals
    • 8.9.2. Reference Laboratories
    • 8.9.3. Academic & Research Institutes
    • 8.9.4. Others
  • 8.10. Market Attractiveness Analysis

9. South Asia & Oceania Lung Cancer Liquid Biopsy Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Product
    • 9.2.3. By Technology
    • 9.2.4. By Biomarker
    • 9.2.5. By Indication
    • 9.2.6. By Sample
    • 9.2.7. By End User
  • 9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 9.4.1. Instruments
    • 9.4.2. Kits and Reagents
    • 9.4.3. Software and Services
  • 9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 9.5.1. Multi-gene-parallel Analysis (NGS)
    • 9.5.2. Single Gene Analysis (PCR Microarrays)
  • 9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 9.6.1. Cell-free DNA (cfDNA)
    • 9.6.2. Circulating tumor DNA (ctDNA)
    • 9.6.3. Extracellular Vesicles (EVs)
    • 9.6.4. Circulating Tumor Cells (CTC)
    • 9.6.5. Others
  • 9.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 9.7.1. Small Cell Lung Cancer (SCLC)
    • 9.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 9.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 9.8.1. Blood
    • 9.8.2. Cerebrospinal Fluid (CSF)
    • 9.8.3. Plasma
    • 9.8.4. Serum
    • 9.8.5. Others
  • 9.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 9.9.1. Hospitals
    • 9.9.2. Reference Laboratories
    • 9.9.3. Academic & Research Institutes
    • 9.9.4. Others
  • 9.10. Market Attractiveness Analysis

10. Latin America Lung Cancer Liquid Biopsy Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Product
    • 10.2.3. By Technology
    • 10.2.4. By Biomarker
    • 10.2.5. By Indication
    • 10.2.6. By Sample
    • 10.2.7. By End User
  • 10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 10.4.1. Instruments
    • 10.4.2. Kits and Reagents
    • 10.4.3. Software and Services
  • 10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 10.5.1. Multi-gene-parallel Analysis (NGS)
    • 10.5.2. Single Gene Analysis (PCR Microarrays)
  • 10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 10.6.1. Cell-free DNA (cfDNA)
    • 10.6.2. Circulating tumor DNA (ctDNA)
    • 10.6.3. Extracellular Vesicles (EVs)
    • 10.6.4. Circulating Tumor Cells (CTC)
    • 10.6.5. Others
  • 10.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 10.7.1. Small Cell Lung Cancer (SCLC)
    • 10.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 10.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 10.8.1. Blood
    • 10.8.2. Cerebrospinal Fluid (CSF)
    • 10.8.3. Plasma
    • 10.8.4. Serum
    • 10.8.5. Others
  • 10.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 10.9.1. Hospitals
    • 10.9.2. Reference Laboratories
    • 10.9.3. Academic & Research Institutes
    • 10.9.4. Others
  • 10.10. Market Attractiveness Analysis

11. Middle East & Africa Lung Cancer Liquid Biopsy Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Product
    • 11.2.3. By Technology
    • 11.2.4. By Biomarker
    • 11.2.5. By Indication
    • 11.2.6. By Sample
    • 11.2.7. By End User
  • 11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2025-2032
    • 11.4.1. Instruments
    • 11.4.2. Kits and Reagents
    • 11.4.3. Software and Services
  • 11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2025-2032
    • 11.5.1. Multi-gene-parallel Analysis (NGS)
    • 11.5.2. Single Gene Analysis (PCR Microarrays)
  • 11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2025-2032
    • 11.6.1. Cell-free DNA (cfDNA)
    • 11.6.2. Circulating tumor DNA (ctDNA)
    • 11.6.3. Extracellular Vesicles (EVs)
    • 11.6.4. Circulating Tumor Cells (CTC)
    • 11.6.5. Others
  • 11.7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2025-2032
    • 11.7.1. Small Cell Lung Cancer (SCLC)
    • 11.7.2. Non-Small Cell Lung Cancer (NSCLC)
  • 11.8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2025-2032
    • 11.8.1. Blood
    • 11.8.2. Cerebrospinal Fluid (CSF)
    • 11.8.3. Plasma
    • 11.8.4. Serum
    • 11.8.5. Others
  • 11.9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2025-2032
    • 11.9.1. Hospitals
    • 11.9.2. Reference Laboratories
    • 11.9.3. Academic & Research Institutes
    • 11.9.4. Others
  • 11.10. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. Bio-Rad Laboratories, Inc.
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Products
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Agilent Technologies, Inc.
    • 12.3.3. Oncocyte Corporation
    • 12.3.4. NeoGenomics Laboratories
    • 12.3.5. Lepu Medical Technology(Beijing)Co.,Ltd
    • 12.3.6. QIAGEN
    • 12.3.7. Thermo Fisher Scientific Inc.
    • 12.3.8. Illumina, Inc.
    • 12.3.9. F. Hoffmann-La Roche Ltd
    • 12.3.10. Sysmex Corporation
    • 12.3.11. BioView
    • 12.3.12. Guardant Health, Inc
    • 12.3.13. SOPHiA GENETICS
    • 12.3.14. BioMark Diagnostics
    • 12.3.15. DELFI Diagnostics, Inc.
    • 12.3.16. Freenome Holdings, Inc.
    • 12.3.17. Foresight Diagnostics, Inc.
    • 12.3.18. Foundation Medicine, Inc.
    • 12.3.19. Pillar Biosciences, Inc.
    • 12.3.20. Caris Life Sciences

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations